Kalkine Media ASX Share Market News & Research
Sign Up/Login
https://kalkinemedia.com/resources/assets/public/img/flags/au.png AUS
https://kalkinemedia.com/resources/assets/public/img/flags/nz.png NZ
https://kalkinemedia.com/resources/assets/public/img/flags/uk.png UK
https://kalkinemedia.com/resources/assets/public/img/flags/ca.png CA
https://kalkinemedia.com/resources/assets/public/img/flags/us.png USA
https://kalkinemedia.com/resources/assets/public/img/flags/fr.png FRA
https://kalkinemedia.com/resources/assets/public/img/flags/de.png GER
https://kalkinemedia.com/resources/assets/public/img/flags/es.png ESP
https://kalkinemedia.com/resources/assets/public/img/flags/it.png ITA
https://kalkinemedia.com/resources/assets/public/img/flags/nl.png NLD
https://kalkinemedia.com/resources/assets/public/img/flags/pt.png PRT
https://kalkinemedia.com/resources/assets/public/img/flags/se.png SWE
https://kalkinemedia.com/resources/assets/public/img/flags/gr.png GRC
https://kalkinemedia.com/resources/assets/public/img/flags/in.png IND
https://kalkinemedia.com/resources/assets/public/img/flags/pl.png POL
https://kalkinemedia.com/resources/assets/public/img/flags/br.png BRA
https://kalkinemedia.com/resources/assets/public/img/flags/za.png ZAF
https://kalkinemedia.com/resources/assets/public/img/flags/ru.png RUS
https://kalkinemedia.com/resources/assets/public/img/flags/cn.png CHN
https://kalkinemedia.com/resources/assets/public/img/flags/ae.png UAE
Kalkine Media ASX Share Market News & Research

Tevard Biosciences Names Dr. Elisabeth Gardiner Chief Scientific Officer to Lead Next Phase of tRNA-Based Therapies

June 10, 2025 08:05 AM EDT | By News File Corp
Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
Tevard Biosciences Names Dr. Elisabeth Gardiner Chief Scientific Officer to Lead Next Phase of tRNA-Based Therapies
Image source: Kalkine Media

Recent News

thumbnail

Westbridge Renewable Energy to Present at Canadian Climate Investor Co...

thumbnail

Forge Resources Announces the Appointment of Gordon Neal to Its Board...

thumbnail

ESGold Corp. Provides Corporate Update as Construction Progresses and...

thumbnail

Argo Living Soils Corp. Appoints Scott Smale as President and CEO

Boston, Massachusetts--(Newsfile Corp. - June 10, 2025) - Tevard Biosciences, Inc., a privately held biotechnology company pioneering tRNA-based therapies to cure a broad range of genetic diseases, today announced the appointment of Elisabeth Gardiner, Ph.D., as Chief Scientific Officer. With more than 25 years of leadership in drug discovery and development across the biotech and pharmaceutical sectors, Dr. Gardiner brings deep translational expertise that will accelerate Tevard's mission to develop effective and durable tRNA-based therapies targeting the root cause of disease. As CSO, she will lead scientific strategy and R&D operations to expand Tevard's novel platform of engineered suppressor tRNAs, which recently demonstrated the first sustained restoration of full-length dystrophin in a Duchenne Muscular Dystrophy (DMD) model.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • Dr. Gardiner's experience scaling discovery and translational programs will be critical as Tevard advances their lead program toward the clinic and expands their pipeline across additional indications.
  • Tevard Biosciences is working to unlock the potential of tRNA-based therapies. The company's programs are based on its novel Suppressor tRNA technology platform that uses a viral vector to insert the normal amino acid at the site of the premature stop codon.
  • Tevard's lead program targeting TTN-related dilated cardiomyopathy is advancing rapidly, with new data expected in the near future.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/7294/255057_figure1_550.jpg

Click image above to view full announcement.

About Tevard Biosciences 
Tevard Biosciences is pioneering tRNA-based and other mRNA-modulating therapies to cure a broad range of genetic diseases. The privately held biotechnology company was founded by renowned scientists along with life science executives and entrepreneurs who are also fathers of children with rare diseases. Tevard is advancing the use of its novel suppressor tRNA platform in heart disease, muscular dystrophies, and neurological disorders. For more information, please visit www.tevard.com.

Contacts:

Michelle Linn
[email protected]

Source: Tevard

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/255057

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media Incorporated (“Kalkine Media, we or us”), Business Number: 720744275BC0001 and is available for personal and non-commercial use only. The advice given by Kalkine Media through its Content is general information only and it does not take into account the user’s personal investment objectives, financial situation and specific needs. Users should make their own enquiries about any investment and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media is not registered as an investment adviser in Canada under either the provincial or territorial Securities Acts. Some of the Content on this website may be sponsored/non-sponsored, as applicable, however, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used in the Content are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used in the Content unless stated otherwise. The images/music that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

CA_Premium_Article

Sponsored Articles

1

Explained: What is SpendTheBits merchant portal and how to use it

2

Benefits of using SpendTheBits app for users and retail merchants

3

An overview of SpendTheBits’ decentralized merchant solution for BTC &...

4

Is investing art or science? KB Crypto has the answer

5

5 factors that make KB Crypto stand out in crypto hedge fund space

Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.